Dr. Laura L. Tenner
Claim this profileNebraska Medicine-Bellevue
Studies Cancer
Studies Colorectal Cancer
7 reported clinical trials
17 drugs studied
Area of expertise
1Cancer
Stage IV
Stage III
DPD negative
2Colorectal Cancer
Stage IV
dMMR positive
MSI-H positive
Affiliated Hospitals
Clinical Trials Laura L. Tenner is currently running
Nivolumab + Standard Treatment
for Stomach and Esophageal Cancer
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Adding nivolumab to ramucirumab and paclitaxel may work better to treat patients with advanced stomach or esophageal cancer.
Recruiting1 award Phase 2 & 320 criteria
Nivolumab + Chemotherapy
for Anal Cancer
This trial is testing whether adding nivolumab to standard chemotherapy is more effective for patients with metastatic anal cancer. Nivolumab helps the immune system fight cancer, while chemotherapy kills or stops cancer cells from growing. Nivolumab has shown significant effectiveness in treating metastatic squamous cell carcinoma of the anal canal.
Recruiting2 awards Phase 321 criteria
More about Laura L. Tenner
Clinical Trial Related1 year of experience running clinical trials · Led 7 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Laura L. Tenner has experience with
- Cisplatin
- Carboplatin
- Temozolomide
- Capecitabine
- Nivolumab
- Dostarlimab
Breakdown of trials Laura L. Tenner has run
Cancer
Colorectal Cancer
Pancreatic Neuroendocrine Tumors
Neuroendocrine Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Laura L. Tenner specialize in?
Laura L. Tenner focuses on Cancer and Colorectal Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Laura L. Tenner currently recruiting for clinical trials?
Yes, Laura L. Tenner is currently recruiting for 5 clinical trials in Bellevue Nebraska. If you're interested in participating, you should apply.
Are there any treatments that Laura L. Tenner has studied deeply?
Yes, Laura L. Tenner has studied treatments such as Cisplatin, Carboplatin, Temozolomide.
What is the best way to schedule an appointment with Laura L. Tenner?
Apply for one of the trials that Laura L. Tenner is conducting.
What is the office address of Laura L. Tenner?
The office of Laura L. Tenner is located at: Nebraska Medicine-Bellevue, Bellevue, Nebraska 68123 United States. This is the address for their practice at the Nebraska Medicine-Bellevue.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.